Useful Links
Scientific Committee
Click on the image to view biography

Debananda Pati
Professor, Baylor College of Medicine, USA
Professor Pati is a highly accomplished cancer biologist who is an internationally recognized leader in the field of chromosomal cohesion and Separation and its role in carcinogenesis. He has a highly impressive track record not only in basic biology of chromosomal cohesion and separation, but devising novel and innovative approaches to target the cohesin pathway for treating refractory human cancers. He is widely recognized nationally and internationally as a creative and innovative scientist and is specifically recognized for his identification and targeting of the cohesin-protease, Separase for cancer therapy. Separase, an enzyme important for resolving chromosomal cohesion, is a novel oncogene and promoter of aneuploidy and tumorigenesis that Professor Pati demonstrated is an ideal target for cancer therapy. His laboratory was first to show that Separase is an oncogene and aneuploidy promoter. In a series of publications in high impact journals, Professor Pati and his colleagues demonstrated that overexpression of Separase in mouse models not only induces aneuploidy but also results in tumorigenesis.

Xiaoping Sun
Professor, University of Texas MD Anderson Cancer Center, USA
Xiaoping Sun completed his MD at Zhejiang Medical University, Hangzhou, China in 1984, and his PhD at Catholic University of Nijmegen, The Netherlands, and Shanghai Institute of Cell Biology, Chinese Academy of Sciences, Shanghai, China in 1994. He received postdoctoral fellowship training at the Salk Institute for Biological Studies, La Jolla, California, USA from 1994 to 1998. His medical residency in anatomical and clinical pathology was completed at Northwestern University Medical School, Chicago, Illinois, USA in 2002, and his hematopathology fellowship at The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA in 2003. He then became an assistant professor and subsequently associated professor and professor in the Department of Laboratory Medicine at UT MD Anderson. Besides his patient care clinical service in the core lab at UT MD Anderson, he runs a research lab that works on leukemogenesis, leukemia progression and drug resistance, B-cell acute lymphoblastic leukemia, and B-cell development.

Yun Gong
Professor, University of Texas MD Anderson Cancer Center, USA
Yun Gong received MD degree in 1984 and then finished her post-graduate Pathology training in 1989 at Zhejiang Medical University in China. She then worked as a post-doctor and Research Associate in the Shanghai Institute of Cell Biology, Chinese Academy of Sciences; Catholic University of Nijmegen, The Netherlands; and The Scripps Research Institute, La Jolla, California. From 1998 to 2002, she received her residency training in Anatomic and Clinical Pathology at Northwestern University Medical School in Chicago, followed by one-year cytopathology fellowship training at MD Anderson Cancer Center. From 2003, she became a faculty member at the Dept. of Pathology, MD Anderson Cancer Center, and currently is a Full Professor. She has numerous publications in the fields of breast cancer research and cytopathology (120 peer-review articles, 18 invited articles, 6 book chapters and 1 book, 118 abstracts). She is an important collaborator of two IBC research projects that were funded by Susan G. Komen Promise Grant. She is a Guest Editor of Breast Diseases: Year Book of Oncology since 2011, a member of the study section of MD Anderson Institutional Research Grant Program, and was a reviewer for NCI/NIH on Business Innovation Research Contract Proposals in 2009 and 2013.

Anissa Boumlic-Courtade
Associate Director , Merck, France
Anissa Boumlic-Courtade, PhD is Associate Director for the vaccine initiative in EMEA with Merck. She joined Merck in 2009 (formerly Millipore) after research experience in various institute including Pasteur Institute of Athens and the CNRS (National Center for Research, France). She has held various positions focused on downstream processing, virus safety, and monoclonal antibody and vaccine process development and manufacturing. She holds a M. Sc. in Biotechnology Engineering from the Ecole Supérieure de Biotechnologie(ESBS) de Strasbourg (France) and a PhD in Molecular Biology & Biochemistry specialized in Virology
from the University of Strasbourgco-directed with the University of Thessaly (Greece).

Sheik Mohammad Fazle Akbar
Principal Investigator, Toshiba General Hospital, Japan
Sheikh Mohammad Fazle Akbar has graduated in Medicine and Surgery from Bangladesh in 1980 and received his PhD in Medical Sciences from Japan in 1993. Being a post-graduate fellow from 1994-1996, he worked as full Faculty Member at the Graduate School of Medicine, Ehime University, Japan from 1996-2008. In 2008, he joined Toshiba General Hospital, Tokyo, Japan as Principal Investigator. He has worked to elucidate pathogenesis of chronic liver diseases and hepatocellular carcinoma; subsequently developed therapeutic vaccine for HBV transgenic mice and presently he has been conducting pilot studies and clinical trials in patients with CHB with Therapeutic Vaccines for last one decade to optimize a safe, effective and clinical viable regimen of this approach in CHB patients. He has authored more than one hundred scientific articles in peer-reviewed journals.

Ahmed Bouzidi
CEO, Vaxeal Group, Switzerland
AHMED BOUZIDI is the Chief Executive Officer Of Vaxeal Group, Vevey, Switzerland. He is also a Board Member of vaccines Europe - Brussels, Belgium. Ahmed Bouzidi is the founder of Vaxeal. He founded and managed SEDAC-Therapeutics inc., a leading biotech pioneer in peptide-based therapeutic vaccines (exit by Leveraged Buy Out), and Biophysiomics inc. (acquired by Chengdu Kuachang Science & Technology, China). He is a board member of Vaccines Europe and of the European Biopharmaceutical Enterprises (EBEbiopharma), and is a Senior Associate of the Royal Society of Medicine. He held previously senior advisory positions with Chinese pharmaceutical companies and public institutions, and worked 10 years as senior researcher at the LFB. He holds a Master degree in Animal Biology (University of Lille, France), a PhD in Cellular Biology, and a MBA in Finance (University of New Hampshire, USA)
Scientific Sessions
Abstract Submission : January 31, 2023
Early Bird Registration : January 31, 2023
Registration Categories
Abstract Submission : January 31, 2023
Early Bird Registration : January 31, 2023
Awards
Participants desiring to be considered for one of these awards need to specify their interest after their submission of the required abstract. Selected participants will be awarded under the following categories:
- Outstanding Submitted Abstract
- Best Research of the conference as evaluated by the Scientific Committee
- Best Poster of the conference depending on the rating given.
- Young Researcher Award under YRF category to encourage budding scientists/ researcher.
Selected participants will receive upto $1500 (USD) scholarship. Decisions will be made based on evaluation of the submitted abstract by the Scientific Committee. The decision made by the Scienctific Committe would be final. We want you to grab this opportunity and participate in the conference...!
Past Conference Report
Global Cancer Meet & Expo 2017 Past Conference Report:
Linkin Science has successfully completed Global Cancer Meet & Expo conference which was held during December 04-06, 2017 in Dubai. We thank all our expertise Scientific Committee Members who have been the constant support for the conference.
Linkin Science would like to greet all the Honourable guests, Keynote Speakers, Delegates, Media Partners and Exhibitors for their participation.
The keynote speakers include:
- Xiaoping Sun, University of Texas MD Anderson Cancer Center, USA
- Debananda Pati, Baylor College of Medicine, USA
- Yun Gong, University of Texas MD Anderson Cancer Center, USA
- Sheik Mohammad Fazle Akbar, Toshiba General Hospital, Japan
- Ahmed Bouzidi ,CEO of Vaxeal Group, Switzerland
The Global Excellence award winners for Cancer Meet 2017 are:
- Shafaq Maqsood, Shaukat Khanum Memorial Cancer hospital and Research, Pakistan (Poster category)
- Ambreen Muzaffar, Shifa International Hospitals LTD, Pakistan (Poster Category)
- Zarka Samoon, Aga Khan University Hospital, Pakistan (For Young Researcher Forum Category)
The 2nd Global Cancer Meet & Expo is scheduled during August 27-29, 2018 at ROME in ITALY. Hope to see you all at this international platform to explore your research in Oncology and Cancer research.
Global Cancer Meet & Expo 2018 Past Conference Report:
Linkin Science has successfully completed 2nd Global Cancer Meet & Expo conference which was held during August 27-28, 2018 in Rome, Italy. We thank all our expertise Scientific Committee Members who have been the constant support for the conference.
Linkin Science would like to greet all the Honourable guests, Keynote Speakers, Delegates, Media Partners and Exhibitors for their participation.
The keynote speakers include:
- Debananda Pati, Baylor College of Medicine, USA
- Aurelija Vaitkuviene, Vilnius University, Vilnius
- Graeme Williams, Harvard, UK
- Henrik G Bohr, Technical University of Denmark, Denmark
- Shi-Ming Tu, Anderson Cancer Center, USA
The 3rd Global Cancer Meet & Expo is scheduled during April 27-29, 2022 at Amsterdam, Netherlands. Hope to see you all at this international platform to explore your research in Oncology and Cancer research.